Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Peroxisome Proliferator-Activated Receptor (PPAR) family and related metabolic nuclear receptors, such as the Farnesoid X Receptor (FXR) and Liver X Receptor (LXR), are ligand-activated transcription factors that serve as essential sensors for metabolic flux [2, 7]. These receptors regulate systemic energy homeostasis by controlling the expression of genes involved in lipid metabolism, glucose transport, and bile acid synthesis [4, 11]. PPARα is primarily involved in fatty acid oxidation in the liver and heart, while PPARγ is the master regulator of adipogenesis and insulin sensitivity in peripheral tissues [9, 12]. Related receptors like FXR and LXR manage bile acid levels and cholesterol transport, respectively, often working in concert with PPARs through heterodimerization with the Retinoid X Receptor (RXR) [8, 10]. Dysregulation of these nuclear receptor pathways is a hallmark of metabolic syndrome, type 2 diabetes, and non-alcoholic steatohepatitis (NASH) [4, 6]. Consequently, they are major therapeutic targets; fibrates and thiazolidinediones are established treatments for dyslipidemia and diabetes, while newer selective and multi-receptor agonists are being developed to treat chronic liver diseases and complex metabolic disorders [12, 13]. However, therapeutic use is often limited by side effects such as weight gain, fluid retention, and pruritus, necessitating the development of more selective modulators [4, 8].
Agonism of specific nuclear receptor isoforms (PPARα, PPARβ/δ, PPARγ, FXR, or LXR) leads to heterodimerization with the Retinoid X Receptor (RXR). These complexes bind to specific response elements in the promoter regions of target genes, recruiting co-activators and initiating the transcription of genes involved in lipid oxidation, glucose transport, and bile acid homeostasis [8, 10, 12].
11 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Peroxisome proliferator-activated receptor family and related metabolic nuclear receptors (PPAR family) (PPAR family).